证券代码：603367 证券简称：辰欣药业 公告编号：2025-017 辰欣药业股份有限公司 关于 2024 年年度利润分配方案的公告 （1）利润分配方案的具体内容 根据大信会计师事务所（特殊普通合伙）出具的《审计报告》，截至 2024 年 12 月 31 日，公司未分配利润为人民币 3,343,534,134.31 元,经董事会审议， 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每 10 股派发现金红利 2.20 元（含税），不以公积金转增股本，不送红 股。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本 发生变动的，拟维持每股分配比例不变，相应调整分配总额，并将在相关公告中 披露。 公司不存在触及《上海证券交易所股票上市规则（2024 年 4 月修订）》 （以下简称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其 他风险警示的情形。 本次利润分配方案已经公司第五届董事会第八次会议审议通过，尚需 提 ...

辰欣药业股份有限公司 非经营性资金占用及其他关 联资金往来情况汇总表的专 项审计报告 大信专审字[2025]第 3-00160 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（bttp://acc.mof.gov.cn）"进行 院国际大厦 22 层 2206 邮编 100083 WIJYIGE Certified Public Accountants I I P 知春路 1 号 Room 2206 22/F, Xueyuan International Tower No 1 Zhichun Road, Haidian Dist Beijing, China, 100083 由话 Telenhone: +86 (10) 82330558 佳首 Fay. +86 (10) 82327668 网址 Internet: www.daxincna.com.cn 非经营性资金占用及其他关联资金往来情况汇总表的 专项审计报告 大信专审字[2025]第 3-00160 号 辰欣药业股份有限公司全体 ...

辰欣药业股份有限公司 内控审计报告 大信审字[2025]第 3-00326 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.grv.cn/ 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn) " 进行查 cc.mof.gov.cn) 报告编码:京253002 WUYIGE Certified Public Accountant: Room 2206 22/F. Xuevuan International Toy No.1 Zhichun Road, Haidian Disf Beijing China 100083 = Telenhone; +86 (10) 82330558 +86 (10) 82327 www.daxincna.com.cn 内部控制审计报告 大信审字[2025]第 3-00326 号 辰欣药业股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, ...

辰欣药业股份有限公司 审 计 报 告 大信审字[2025]第 3-00323 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F,Xueyuan International Tower No.1 Zhichun Road,Haidian Dist. Beijing,China,100083 审计报告 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 大信审字[2025]第 3-00323 号 辰欣药业股份有限公司全体股东： 一、审计意见 三、关键审计事项 关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的事项。这些事 项的应对以对财务报表整体进行审计并形成审计意见为背景，我们不对这些事项单独发表意 见。 ...

第二条 本制度所称证券投资，是指在证券市场投资有价证券的行为，包括但 不限于新股配售或者申购、证券回购、股票及存托凭证投资、债券投资以及上海 证券交易所认定的其他投资行为。 本制度所称的金融衍生品交易业务主要包括远期、期货、掉期（互换）、期权 等产品或者混合上述产品特征的金融工具交易、场外衍生品交易等。衍生品的基 础资产既可以是证券、指数、利率、汇率、货币、商品等标的，也可以是上述标 的的组合。 以下情形不适用本制度证券投资及金融衍生品规范的范围： 辰欣药业股份有限公司 证券投资与金融衍生品交易管理制度 第一章 总则 第一条 为规范辰欣药业股份有限公司（以下简称"公司"）及下属子公司证券 投资及金融衍生品交易业务的管理，强化风险控制，防范交易风险，保护投资者 的权益和公司利益，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》等有关法律、法规、规范性文件及《辰欣药业股份有限 公司章程》(以下简称"公司章程")的有关规定，结合公司的实际情况，特制定本制 度。 第四条 公司进行证券投资与金融衍生品交易业务应当遵循合 ...

辰欣药业股份有限公司 2024年度独立董事述职报告 辰欣药业股份有限公司 一、独立董事的基本情况 截至2024年12月31日，公司第五届董事会在任独立董事张自然先生、蔡文春 先生、王唯佳女士共三名，占公司董事会人数的三分之一，符合相关法律法规中 关于上市公司独立董事人数比例和专业配置的要求，前述3名独立董事在行业、 企业管理、法律和财务等方面具有较高的专业水平和丰富的实践经验，符合相关 法律法规的要求，且不存在影响独立性的情况。 1、工作履历、专业背景及相关兼职情况 王唯佳，女，中国国籍，无境外永久居留权，1966年生，大学学历，正高级 经济师，山东大学汉语言文学专业本科，1985年7月-2005年5月山东济南医药采 购供应站任财务物价处副处长，2005年5月-2007年5月任山东省医药集团协会秘 书处主管；2007年5月起借调省医药行业协会秘书处工作历任副秘书长、秘书长， 2013年1月起调任山东省医药行业协会专职秘书长、常务副会长，现任省医药行 业协会执行会长。2024年2月至今，王唯佳女士任辰欣药业独立董事。 2、不存在影响独立性的情况说明 报告期内本人任职期间，不存在持有公司股份情形，在公司未有担任除 ...

辰欣药业股份有限公司 2024年度独立董事述职报告 辰欣药业股份有限公司 2024年度独立董事述职报告 本人作为辰欣药业股份有限公司（以下简称 "公司"或"辰欣药业"） 的独立董事，2024年度，严格按照《公司法》《上市公司治理准则》《上市公 司独立董事管理办法》《上市公司独立董事履职指引》等法律法规和《公司章 程》的规定，本着客观、公正、独立性的原则，认真履行独立董事的职责，对 公司重大事项发表了公正、客观的独立意见，维护了公司的规范化运作及全体 股东的整体利益。现将本人在2024年度履行独立董事职责情况报告如下： 一、独立董事的基本情况 截至2024年12月31日，公司第五届董事会在任独立董事张自然先生、蔡文春 先生、王唯佳女士共三名，占公司董事会人数的三分之一，符合相关法律法规中 关于上市公司独立董事人数比例和专业配置的要求，前述3名独立董事在行业、 企业管理、法律和财务等方面具有较高的专业水平和丰富的实践经验，符合相关 法律法规的要求，且不存在影响独立性的情况。 1、工作履历、专业背景及相关兼职情况 本人张自然，男，1965 年生，医学博士，制药高级工程师，执业药师。1991 年毕业于华西医科大学（现 ...

辰欣药业股份有限公司 2024年度独立董事述职报告 辰欣药业股份有限公司 2024年度独立董事述职报告 本人作为辰欣药业股份有限公司（以下简称 "公司"或"辰欣药业"） 的独立董事，2024年度，严格按照《公司法》《上市公司治理准则》《上市公 司独立董事管理办法》等法律法规和《公司章程》的规定，本着客观、公正、 独立性的原则，认真履行独立董事的职责，对公司重大事项发表了公正、客观 的独立意见，维护了公司的规范化运作及全体股东的整体利益。现将本人在 2024年度履行独立董事职责情况报告如下： （一）2024年出席董事会及股东大会会议情况 一、独立董事的基本情况 截至2024年12月31日，公司第五届董事会在任独立董事张自然先生、蔡文春 先生、王唯佳女士共三名，占公司董事会人数的三分之一，符合相关法律法规中 关于上市公司独立董事人数比例和专业配置的要求，前述3名独立董事在行业、 企业管理、法律和财务等方面具有较高的专业水平和丰富的实践经验，符合相关 法律法规的要求，且不存在影响独立性的情况。 1、工作履历、专业背景及相关兼职情况 蔡文春，男，中国国籍，无境外居留权，1974年生，山东财经大学副教授， 燕山学院教授 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥920,204,017.65, a decrease of 19.91% compared to ¥1,148,946,834.25 in the same period last year[5] - Net profit attributable to shareholders was ¥143,544,555.30, down 11.86% from ¥162,863,217.96 year-on-year[5] - Basic and diluted earnings per share were both ¥0.32, reflecting an 11.11% decline from ¥0.36 in the same period last year[6] - Total revenue for Q1 2025 was RMB 920,204,017.65, a decrease of 19.93% compared to RMB 1,148,946,834.25 in Q1 2024[20] - Operating profit for Q1 2025 was ¥124,230,926.58, down from ¥142,970,237.88 in Q1 2024, reflecting a decline of 13.1%[34] - Net profit for Q1 2025 was ¥116,141,414.65, compared to ¥129,419,933.08 in Q1 2024, representing a decrease of 10.2%[34] - The total comprehensive income for the period was CNY 145,066,811.69, compared to CNY 163,945,932.09, reflecting a decrease of about 11.5%[22] Cash Flow - The net cash flow from operating activities decreased by 76.53%, amounting to ¥57,513,417.42 compared to ¥245,031,646.54 in the previous year[5] - The net cash flow from operating activities was CNY 57,513,417.42, significantly lower than CNY 245,031,646.54 in the same period last year, reflecting a decline of approximately 76.6%[24] - In Q1 2025, the net cash flow from operating activities was ¥20,755,809.71, a significant decrease of 88.6% compared to ¥182,959,351.08 in Q1 2024[36] - The net cash flow from investing activities was negative at CNY -348,187,435.26, compared to CNY -221,438,840.30 in the same period last year, indicating a worsening of approximately 57.3%[26] - The net cash flow from investment activities was -¥344,803,552.58 in Q1 2025, worsening from -¥234,003,505.84 in Q1 2024[37] - The net increase in cash and cash equivalents for Q1 2025 was -¥375,710,743.19, compared to -¥59,155,775.30 in Q1 2024, indicating a worsening liquidity position[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,597,520,023.49, a slight increase of 0.58% from ¥7,553,814,810.05 at the end of the previous year[6] - Current assets as of March 31, 2025, totaled RMB 4,887,371,204.72, slightly down from RMB 4,961,714,730.43 as of December 31, 2024[16] - Total liabilities decreased to RMB 1,461,232,590.39 from RMB 1,566,866,075.86, a decline of 6.73%[18] - Total current assets decreased slightly from ¥4,375,673,177.87 as of December 31, 2024, to ¥4,261,967,480.90 as of March 31, 2025[29] - Total non-current assets increased from ¥2,404,364,267.86 as of December 31, 2024, to ¥2,522,646,806.16 as of March 31, 2025[29] - Total liabilities decreased from ¥1,403,564,367.43 as of December 31, 2024, to ¥1,291,999,794.11 as of March 31, 2025[30] - The company's total equity increased from ¥5,376,473,078.30 as of December 31, 2024, to ¥5,492,614,492.95 as of March 31, 2025[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,375[11] - The largest shareholder, Chenxin Technology Group Co., Ltd., held 26.26% of the shares, totaling 118,891,080 shares[12] - The company reported no significant changes in major shareholders or their participation in financing activities[13] Investment and Expenses - The company's investment income increased by 154.79%, indicating a significant rise in investment returns during the reporting period[9] - Research and development expenses were CNY 73,643,696.38, down from CNY 100,074,377.52, showing a reduction of about 26.4% year-over-year[21] - Research and development expenses for Q1 2025 were ¥70,701,621.24, down from ¥81,709,281.41 in Q1 2024, a decrease of 13.5%[34] - The company's total operating costs were CNY 741,656,866.42, a decrease from CNY 954,816,641.05, representing a reduction of about 22.3%[21] - The company reported a financial income of ¥6,272,927.25 in Q1 2025, compared to ¥10,438,291.41 in Q1 2024, indicating a decline of 40.5%[34]

Financial Performance - The company's operating revenue for 2024 was CNY 3,981,572,232.95, a decrease of 10.77% compared to CNY 4,462,348,636.07 in 2023 [24]. - The net profit attributable to shareholders for 2024 was CNY 508,906,193.71, down 2.38% from CNY 521,338,330.89 in 2023 [24]. - The total profit for 2024 was 576 million RMB, down 3.37% year-on-year [35]. - The net profit attributable to the parent company was 509 million RMB, a decrease of 2.38% compared to the previous year [35]. - The net profit after deducting non-recurring gains and losses was 426 million RMB, down 5.63% year-on-year [35]. - The company's cash flow from operating activities increased by 26.51% to CNY 570,848,680.25 in 2024, compared to CNY 451,240,761.60 in 2023 [24]. - The basic earnings per share for 2024 was CNY 1.12, a decrease of 2.61% from CNY 1.15 in 2023 [26]. - The weighted average return on equity for 2024 was 8.66%, down from 9.49% in 2023, a decrease of 0.83 percentage points [26]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.44 per share (including tax) for the fiscal year 2024, with a total distribution amount of RMB 199,211,816.76, accounting for 39.15% of the net profit attributable to shareholders [6]. - As of December 31, 2024, the total share capital of the company is 452,754,129 shares, with a cash dividend of RMB 0.22 per share already distributed in the first half of 2024 [6]. - The company executed two cash dividend distributions in 2024, totaling approximately 197.41 million yuan and 99.61 million yuan, representing 37.87% and 36.85% of the net profit attributable to shareholders, respectively [158][159]. Governance and Compliance - The company has received a standard unqualified audit report from Da Xin Certified Public Accountants, ensuring the accuracy and completeness of the financial report [5]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance [4]. - The company has not violated decision-making procedures in providing guarantees to external parties [8]. - The company has not faced any issues that would prevent more than half of the directors from guaranteeing the authenticity and completeness of the annual report [8]. - The company maintains a robust governance structure, ensuring compliance with legal regulations and promoting transparency in information disclosure [121]. Research and Development - The company has over 100 ongoing research projects focusing on complex injection preparations, controlled-release oral solid preparations, and other therapeutic areas [38]. - R&D investment accounts for over 8% of the company's revenue, supporting its transformation and sustainable development [56]. - The company invested CNY 343 million in R&D for 2024, with over 100 projects in progress focusing on complex injections, controlled-release oral solid preparations, and other therapeutic areas [86]. - The company is focusing on innovative drugs targeting diseases with unmet treatment needs, with several new drugs in various clinical trial phases [87]. - The company is actively pursuing collaborations for R&D projects under the MAH policy, aiming to expand its product offerings [85]. Market and Product Development - The company is enhancing its marketing strategy by optimizing human resources and performance incentives to improve overall marketing effectiveness [36]. - The company has introduced new products, including Bromfenac Sodium Eye Drops and Dexmedetomidine Hydrochloride Injection, expanding its product portfolio [78]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on complementary businesses [79]. - The company is focusing on expanding its product portfolio in the therapeutic areas of neurology and immunology, with multiple products in various stages of clinical research [92]. Environmental Responsibility - The company has implemented various pollution prevention measures, including the installation of activated carbon treatment equipment for waste gas emissions [178]. - The company has received multiple environmental impact assessments and approvals for its production projects from the Jining Environmental Protection Bureau [179]. - The company reported a total wastewater discharge of 58,642 m³ for the year [186]. - The actual concentration of chemical oxygen demand (COD) in wastewater was 72 mg/L, significantly below the limit of 500 mg/L [186]. - The company has not faced any administrative penalties related to environmental issues during the reporting period [184]. Strategic Outlook - The company provided a future outlook with a revenue guidance of 1,875.1 million for the next quarter, indicating a projected growth rate of 10% [131]. - The company is focusing on optimizing supply chain management and enhancing production efficiency to cope with the pressures of centralized procurement and price competition [111]. - The company is committed to enhancing high-end drug supply capabilities and accelerate the development of innovative drugs and first-generic drugs, as outlined in the "Pharmaceutical Industry High-Quality Development Action Plan (2023-2025)" [111]. - The company is exploring international market expansion, aiming for a year-on-year increase in formulation export scale [114].